Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 61 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer				Phase III				NSABP-R-04 NCT00058474, NSABP-R-04, CALGB-NSABP-R-04
	Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer				Phase III				ECOG-E5204 E5204, NSABP-ECOG-E5204, NCCTG-ECOG-E5204, NCT00303628
	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer or Other Solid Tumors That Cannot Be Removed by Surgery				Phase II, Phase I				CASE-1205 NCI-7325, 7325, NCT00296062
	Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer				Phase II, Phase I				05-345 NCT00307736
	Vorinostat and IV 5FU/LV in Patients With Metastatic Colorectal Cancer				Phase II, Phase I				3C-05-3 NCT00336141
	Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer				Phase II, Phase I				A4061020 NCT00460603
	Phase I Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer				Phase II, Phase I				EGF108991 NCT00536809
	Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer				Phase II, Phase I				2007-0080 NCT00543842
	Erlotinib in Treating Patients With Stage I, Stage II, or Stage III Colorectal Cancer or Adenoma				Phase II, Phase I				UCIRVINE-UCI06-8-01 UCI06-8-01, NCT00754494
	Chemotherapy Administered Every 2 Weeks with or without Pegfilgrastim (Neulasta) in Subjects with Advanced Colon Cancer				Phase II				20020715 NCT00094809


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute